Definium Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-159.0M | $-77.1M | $-50.4M | $-67.3M | $-42.7M | $-23.3M | $-34.7M | $-13.7M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-52.8M | $-42.6M | $-43.0M | $-29.6M | $-29.6M | $-29.4M | $-25.4M | $-17.2M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-316.7M | $42.0M | $35.0M | $15.4M | $-39.5M | $-162.5M | $0 | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $762.3M | $5.3M | $245.9M | $749.0K | $19.7M | $1.0M | $3.8M | $69.4M |
| Net Change in Cash | $392.7M | $4.7M | $237.9M | $-13.4M | $-49.5M | $-190.9M | $-21.5M | $52.2M |
| Free Cash Flow | — | — | — | — | — | — | — | — |